Introduction
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are still recommended as part of prevention of motherto-child transmission (PMTCT) regimens, including option B/Bþ, despite the well described selection of resistance mutations among a large proportion of PMTCT-exposed women and their infected infants [1, 2] . However, these data come predominantly from clinical trials and research cohorts and the frequency of prophylaxis-selected drug resistance in routine programs is less well established [3] .
Although PMTCT dramatically reduces the risk of pediatric HIV infection, it does not entirely prevent transmission [4] . Infants with no PMTCTexposure are at higher risk of infection than PMTCT-exposed infants, but the proportion exposed is a function of population coverage of PMTCT. In many settings, ritonavir-boosted lopinavir (LPV/r)-based regimens are only recommended for infants with reported PMTCT exposure on the assumption that NNRTI-associated mutations rarely occur outside this group. However, the prevalence and patterns of drug resistance in HIV-infected infants with no reported history of PMTCT have not been described.
Our study was designed to describe drug resistance among newly diagnosed, treatment-naive, HIV-infected children under 2 years of age accessing routine services in Johannesburg, South Africa, a year after PMTCT guidelines were changed to support more effective interventions, including wider use of maternal combination antiretroviral therapy (cART) [5, 6] .
Methods
Between January and December 2011, we aimed to recruit all newly diagnosed, treatment-naive HIVinfected infants and young children under 2 years of age at three major hospitals, and two affiliated clinics, in Johannesburg, South Africa. Recruitment was conducted at routine PMTCT follow-up clinics and inpatient services where children were identified during hospitalization. Plasma from venous blood was stored for drug resistance testing. Detailed sociodemographic, clinical, treatment, and PMTCT data were collected during a standardized interview. Maternal and pediatric medical records were sought to confirm drug exposures. PMTCT guidelines in place at the time recommended HIV testing at first antenatal visit with immediate CD4 þ cell testing to determine management. Women with CD4 þ cell count 350 cells/ml or less were initiated on cART with nevirapine/tenofovir/lamivudine recommended as the preferred first-line regimen. Women with CD4 þ cell count more than 350 cells/ml initiated zidovudine from 14 weeks through labor, and single-dose nevirapine and single-dose emtricitabine/tenofovir were given postdelivery. All infants, regardless of maternal regimen or feeding practice, were given daily nevirapine for 6 weeks. Nevirapine was continued daily through breastfeeding for infants whose mothers were not on cART [5, 6] . Mothers signed informed consent and the study was approved by the Institutional Review Boards of the University of the Witwatersrand and Columbia University.
An inhouse population sequencing method of HIV-1 polymerase optimized for subtype C infections and certified by the Virology Quality Assessment Program was undertaken on children's plasma samples [7] . HIV-1 RNA was isolated using a MagNa Pure LC Total Nucleic Acid Isolation kit on the MagNa Pure Automated System. A nested PCR was performed to generate a 1.7 kb amplicon spanning protease and reverse transcriptase genes [7, 8] . PCR products were sequenced using BigDye Terminators v3.1 on an ABI3100 Genetic Analyzer (Applied Biosystems, Foster City, California, USA). Consensus sequences were aligned and manually edited using the Sequencher v5.0 (GeneCodes; Ann Arbor, Michigan, USA). Resistance was defined as the presence of mutations associated with any level of impaired drug susceptibility, using the Stanford algorithm (http://hivdb.stanford.edu/).
Results
Of 385 children initially approached attending the five centers, 292 were enrolled (15 refused, 37 were ineligible, 41 were discharged or died before enrollment). Drug resistance testing was undertaken in 255 children (37 had no blood collected). Three samples were excluded as they were duplicate enrollments, three samples did not amplify, and 19 samples were excluded because the child had initiated cART prior to sample collection, resulting in 230 children in the analysis.
Two-thirds (155/230, 67.4%) of children (median age 19 weeks, youngest 27 days) had been exposed to maternal and/or infant PMTCT. In 89.0% of PMTCT-exposed children, this included a maternal component: cART (n ¼ 28, 18.1%), zidovudine during pregnancy and single-dose nevirapine at delivery (n ¼ 78, 50.3%), zidovudine only during pregnancy (n ¼ 23, 14.8%), or single-dose nevirapine (n ¼ 9, 5.8%). In 97.4% of exposed children, this included infant prophylaxis [nevirapine (n ¼ 129), nevirapine and zidovudine (n ¼ 21), or zidovudine only (n ¼ 1)]. The remaining third (75/ 230, 32.6%) had no self-reported or recorded PMTCT exposures (median age 42 weeks, youngest 32 days). Twelve women of 75 (16.0%) were not tested during pregnancy and 51 (68.0%) reported testing HIV negative during pregnancy; among these women, 52 learned their own HIV status at the same time as child diagnosis.
Among 155 PMTCT-exposed children, 56.8% (88) had any NNRTI mutations, 14.8% (23) had nucleoside reverse transcriptase inhibitor (NRTI) mutations (2.6% had more than one), and 1.3% (2) had protease inhibitor mutations. The most common NNRTI mutation was Y181C (56) constituting 63.6% of 88 children with any NNRTI mutations ( Fig. 1 ). Eighteen of 23 (78.3%) children with NRTI mutations also had NNRTI mutations. One child had multiple protease inhibitor mutations (L10F, M46I, I54V, L76V, V82A) and one only M46L. Based on current drug specificity in the classification of NNRTI mutations (http://hivdb.stanford.edu/) and among the PMTCT-exposed, 54.2% (54) had high-level resistance to nevirapine, 21.9% (34) highlevel resistance to efavirenz, and 2.3% (2) T69N  L74V  V75I  A62V  K70R  V75L  K219Q  T69S  T215F  T215A  D67T  K219E  K219N  K65R  M184I  T69A  T69I   30 resistance to etravirine. The difference was largely driven by Y181C, which is classified as conferring 'intermediate-level' resistance to efavirenz and etravirine.
Among 75 PMTCT-unexposed children, 24.0% (18) had NNRTI mutations, 10.7% (8) had single NRTI mutations, and 1.3% (1) protease inhibitor mutations (M46T). Similarly to PMTCT-exposed, the most common NNRTI mutation was Y181C (8) (Fig. 1) . The prevalence of mutations causing high-level resistance to nevirapine was 17.3% (13) , to efavirenz 6.7% (5) , and none had high-level resistance to etravirine.
There was a strong association between young age at testing and detection of NNRTI mutations in PMTCTexposed children (P < 0.0001) ( Table 1 ). There was no association between age and NNRTI mutations in the unexposed group (P ¼ 0.66). A significantly higher prevalence of NNRTI mutations in the PMTCTexposed vs. unexposed group persisted after adjusting for age (P ¼ 0.003).
Among PMTCT-exposed children, the prevalence of NNRTI mutations was not associated with child sex, viral load, CD4 þ cell count, or breastfeeding in univariable analysis (Table 1) .
NNRTI mutations were more common in children whose mothers had received cART, but all had also received infant prophylaxis. Among the 28 women who had received cART during pregnancy, all but three received an NNRTI-based regimen (11 nevirapine, 14 efavirenz). There was no difference in the prevalence of mutations between these regimens. Lamivudine was used 1676 AIDS 2014, Vol 28 No 11 in all 25 women with stavudine (n ¼ 9), tenofovir (n ¼ 13), or zidovudine (n ¼ 3). Among six of 25 children with NRTI mutations, four mothers had used stavudine and two had used tenofovir. Three mothers had received protease inhibitor-based regimens (LPV/r). One child had no resistance mutations, one had dual class resistance (Y181C, G190A, K219N), and one had multiclass resistance (Y188L and D67T, T69N, K70R, M184V, T215F, K219E and multiple protease inhibitor mutations L10F, M46I, I54V, L76V, V82A).
Very few children were unexposed to infant nevirapine prophylaxis to examine this group separately, but the prevalence of NNRTI mutations was lower if zidovudine was used in addition to nevirapine in univariable analysis (Table 1 ). However, this association was attenuated and was no longer significant if adjusted for infant age at testing. Similarly, the association between longer duration of infant nevirapine prophylaxis and NNRTI mutations ( Table 1) was explained by younger age at testing.
Discussion
In this population of newly diagnosed, treatment-naive HIV-infected infants and young children in five centers in Johannesburg, at least two-thirds had been exposed to some form of PMTCT intervention. NNRTI-associated mutations were detected by population sequencing in the majority (57%) of these PMTCT-exposed children. Had ultrasensitive methods such as allele-specific PCR been applied [9] , this proportion would undoubtedly have been higher. The strongest predictor of NNRTI mutations in the PMTCT-exposed group was young age. This suggests that the decline in NNRTI mutations to below the detection threshold of the assays is a function of time since antiretroviral exposure, as we and others have previously shown [9] [10] [11] .
Infants whose mothers received cART were more likely to have NNRTI-associated mutations. However, infant nevirapine prophylaxis was universal making it impossible to distinguish the independent effects of maternal regimen. Although this study was done before the shift to universal use of cART for PMTCT (Option B/Bþ), our results indicate that no decline in the frequency of resistance in infected children is to be expected based on this change. Nevertheless, with increased maternal cART coverage, the absolute number of newly infected infants should decrease. PMTCT guidelines continue to recommend infant nevirapine prophylaxis even when maternal cART is given during pregnancy and breastfeeding [5, 6] . Whether there is additional benefit of infant prophylaxis in this circumstance is unknown. Infant prophylaxis may confer necessary transmission benefits when maternal antiretrovirals are started late in pregnancy or adherence is poor.
Infants who received nevirapine for a longer time were more likely to be diagnosed at a younger age, presumably because of better access to care. Thus, the apparent relationship between longer duration of nevirapine prophylaxis and more NNRTI-associated mutations is most likely artifact. Given the high rates of NNRTI mutations with single-dose nevirapine [1, 2] , there is likely a ceiling effect with additional doses having minimal relevance for additional selection of NNRTI resistance. Thus, shifts away from Option A (i.e. long duration nevirapine prophylaxis) are unlikely to have an appreciable effect on the frequency of drug resistance in infected children.
As previously shown, Y181C predominates in nevirapine-exposed children in contrast to nevirapine-exposed adults in whom K103N predominates [1, 9] . Whereas Y181C confers high-level resistance to nevirapine, it confers 'intermediate'-level resistance to efavirenz and etravirine. Although use of efavirenz in children under 3 years of age is controversial and not recommended, its use in older children after initial suppression on LPV/r may not be as compromised by past PMTCT exposure as nevirapine-based treatment [12] . Etravirine is not yet available for young children.
Notably, NNRTI-associated mutations were observed in almost a quarter (24%) of newly diagnosed, treatmentnaive children with no reported or recorded PMTCT exposures. We hypothesize that poor maternal recall, lack of understanding, poor record-keeping, or failure to recall exposures in prior pregnancies may explain some of these cases [13] . Mothers may have been infected with and transmitted resistant variants, although rates are higher than expected based on the prevalence of resistance in drug-naive adults from surveillance studies in this population [14] . There may also have been unacknowledged or inadvertent postnatal drug exposures. Measurable levels of antiretrovirals were observed in almost half of HIV-infected adults with undetectable viral load, reporting no prior antiretroviral exposures in one large African trial [15] . Our results indicate that history of PMTCT exposure, even when rigorously ascertained, is a poor means of ruling out NNRTI mutations in the child. Similar data were reported in Swaziland and Zimbabwe [3] using WHOrecommended surveillance methods to assess HIV drug resistance in newly diagnosed, treatment-naive children less than 18 months [16] .
NRTI-associated mutations were observed in 15% of PMTCT-exposed children, but less than 3% had more than one NRTI mutation. No unexposed children had more than one NRTI mutation. Protease inhibitorassociated mutations were rare. The mother of the one child with multiple protease inhibitor-associated mutations had transitioned to second-line therapy during pregnancy. The two children with protease inhibitor mutations, but no history of protease inhibitor exposure had M46L/T, which may arise in the absence of drug pressure.
Introduction of more efficacious PMTCT has reduced perinatal infections in this South African population to less than 3% [17] . Although there are declining numbers of new infections, our data confirm that the majority of newly diagnosed HIV-infected infants and young children will carry NNRTI-resistant virus. Resistanceassociated mutations are also present in a considerable proportion of children with no reported or recorded antiretroviral drug exposures. Together, these observations support the current policy of utilizing LPV/rbased treatment as first-line in all infants and young children [18, 19] .
